Coherus BioSciences (CHRS) Tops Q2 EPS by 7c
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.13 --0%
Revenue Growth %: +37.8%
Financial Fact:
Net income/(loss): 17.77M
Today's EPS Names:
OCCI, PMCB, BRID, More
Revenue Growth %: +37.8%
Financial Fact:
Net income/(loss): 17.77M
Today's EPS Names:
OCCI, PMCB, BRID, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q2 EPS of ($0.19), $0.07 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $14.31 million versus the consensus estimate of $14.41 million.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nvidia’s AI dominance funds historic $150 billion buyback
- Paramount Skydance plans $44.4B notes offering to fund WBD acquisition
- Daré Bioscience receives new U.S. patent for HPV treatment program
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
